NCI/CTEP 8457: A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer
Print this page
NCI/CTEP 8457: A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer
Primary: To determine if addition of bortezomib to fulvestrant improves median PFS compared with fulvestrant alone in postmenopausal women with ER-positive locally advanced inoperable or metastatic breast cancer who have disease that is resistant to aromatase inhibitor therapy
| Protocol Number | 041204 |
|---|---|
| Principal Investigator | Antoinette Tan |
| Phase | Phase II |
| Scope | National |
| Applicable Disease Sites | Breast - Female |
| Therapies Involved | Chemotherapy single agent systemic Chemotherapy multiple agents systemic |
| Drugs Involved | FULVESTRANT BORTEZOMIB |
| Participating Institutions | The Cancer Institute of New Jersey |
For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.
